MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

MDT

87.95

+0.96%↑

117.5

+2.09%↑

VEEV

158.5

+4.65%↑

HQY

79.86

+2.23%↑

TLRY

6.73

+2.28%↑

Home・Akciju saraksts・AnaptysBio Inc

AnaptysBio Inc

Slēgts

SektorsVeselības aprūpe

68.74 -1.63

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

68.39

Max

72.82

Galvenie mērījumi
By Trading Economics
Ienākumi	35M 50M
Pārdošana	32M 108M
Peļņas marža	45.833
Darbinieki	104
EBITDA	29M 68M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+18.72% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 1. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	259M 1.8B
Iepriekšējā atvēršanas cena	70.37
Iepriekšējā slēgšanas cena	68.74

Ziņu noskaņojums

By Acuity

23%

77%

51 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

19.25 / 21.135 Atbalsts un pretestība

AnaptysBio Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. apr. 23:25 UTC

Galvenie ziņu notikumi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

2026. g. 13. apr. 22:45 UTC

Galvenie ziņu notikumi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

2026. g. 13. apr. 18:03 UTC

Peļņas

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

2026. g. 13. apr. 23:58 UTC

Peļņas

Review & Preview: Earnings Time -- Barrons.com

2026. g. 13. apr. 23:49 UTC

Tirgus saruna

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

2026. g. 13. apr. 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher Amid Dollar Weakness -- Market Talk

2026. g. 13. apr. 23:20 UTC

Tirgus saruna

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

2026. g. 13. apr. 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

2026. g. 13. apr. 21:26 UTC

Galvenie ziņu notikumi

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

2026. g. 13. apr. 21:23 UTC

Peļņas

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

2026. g. 13. apr. 21:16 UTC

Peļņas

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

2026. g. 13. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 13. apr. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

2026. g. 13. apr. 19:59 UTC

Tirgus saruna

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

2026. g. 13. apr. 19:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

2026. g. 13. apr. 19:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Correction to Precious Metals Market Talk on April 9

2026. g. 13. apr. 19:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

2026. g. 13. apr. 18:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

2026. g. 13. apr. 18:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

2026. g. 13. apr. 18:43 UTC

Tirgus saruna

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Salīdzinājums

Cenas izmaiņa

AnaptysBio Inc Prognoze

Cenas mērķis

By TipRanks

18.72% augšup

Prognoze 12 mēnešiem

Vidējais 83.22 USD 18.72%

Augstākais 140 USD

Zemākais 50 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

19.25 / 21.135Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

51 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.